sachchida nand rai (33 Ergebnisse)

Paperback. Zustand: Brand New. 76 pages. 8.66x5.91x0.18 inches. In Stock.

hardcover. Zustand: Fine.

hardcover. Zustand: Fine.

Taschenbuch. Zustand: Neu. Neuware -Approximately 200 years ago, James Parkinson had described the major symptoms of a disease that ultimately came to stand his name, i.e. Parkinson¿s disease (PD). Gradually but definitely, our understanding about the disease has got enhanced, still the effective treatment for the disease has not yet been developed. PD leftovers an enormous challenge to those who suffer from it and to those concerned with its supervision. In addition to the problems common to other disabling neurological conditions, the management of PD must take into account the fact that the foundation of pharmacological treatment, levodopa, can ultimately produce dyskinesia, also called drug induced dyskinesia and motor fluctuation. Moreover, there are a number of agents besides levodopa that can help in the management of PD, and there is tempting but unverified prospect that other treatments might protect against worsening neurological disability. Moreover, in developing countries the marketed levodopa preparation is not accessed by individuals suffering from PD. Thus, a substantial amount of judgement is necessary in tailoring individual therapy and in timing treatment initiation.Books on Demand GmbH, Überseering 33, 22297 Hamburg 76 pp. Englisch.

Zustand: New.

Taschenbuch. Zustand: Neu. Parkinson's disease and Mucuna Magic | Sachchida Nand Rai (u. a.) | Taschenbuch | 76 S. | Englisch | 2018 | LAP LAMBERT Academic Publishing | EAN 9786138111825 | Verantwortliche Person für die EU: BoD - Books on Demand, In de Tarpen 42, 22848 Norderstedt, info[at]bod[dot]de | Anbieter: preigu.

hardcover. Zustand: Very Good.

Zustand: New.

Taschenbuch. Zustand: Neu. Neuware -Hace aproximadamente 200 años, James Parkinson describió los principales síntomas de una enfermedad que acabó llevando su nombre, es decir, la enfermedad de Parkinson (EP). Poco a poco, pero definitivamente, nuestra comprensión de la enfermedad ha mejorado, pero aún no se ha desarrollado un tratamiento eficaz para la enfermedad. La EP supone un enorme reto para quienes la padecen y para quienes se ocupan de su supervisión. Además de los problemas comunes a otras afecciones neurológicas discapacitantes, el manejo de la EP debe tener en cuenta el hecho de que la base del tratamiento farmacológico, la levodopa, puede acabar produciendo discinesia, también llamada discinesia inducida por fármacos y fluctuación motora. Además, hay una serie de agentes, aparte de la levodopa, que pueden ayudar en el tratamiento de la EP, y existe la tentadora pero no verificada perspectiva de que otros tratamientos puedan proteger contra el empeoramiento de la discapacidad neurológica. Además, en los países en vías de desarrollo las personas que padecen EP no tienen acceso al preparado de levodopa comercializado. Por lo tanto, se necesita una cantidad sustancial de juicio para adaptar la terapia individual y para programar el inicio del tratamiento.Books on Demand GmbH, Überseering 33, 22297 Hamburg 76 pp. Spanisch.

Zustand: New.

Zustand: New.

Zustand: New.

Zustand: New.

HRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000.

Zustand: New.

Taschenbuch. Zustand: Neu. Neuware - Researchers have tried various effective treatments that prevent the progressive neurodegeneration of neurons within the brain. Parkinson's disease (PD), Alzheimer's disease (AD), and Multiple sclerosis (MS) are some of the most common neurodegenerative diseases (NDDs). Recent Advances in the Treatment of Neurodegenerative Disorders provides interesting updates on treatments of these neurological disorders. Ten chapters have been contributed by experts in pharmacology and give a unique perspective to reader on special topics in this area, including the treatment of neurodegenerative treatment of neurodegenerative disease through ayurveda and phytochemicals, the therapeutic role of vitamins in Parkinson's disease, mushrooms in NDD treatment, MS treatment, ALS treatment and the use of nanoparticles and nano formulations in NDD treatment. This is an informative reference for pharmacologists, medicinal chemists and healthcare professionals (general practitioners and neurologists) seeking updates in the treatment of some common neurodegenerative disorders.

Paperback. Zustand: Brand New. 450 pages. 9.25x7.50x9.25 inches. In Stock.

Hardcover. Zustand: Brand New. 9.25x6.10 inches. In Stock.

Hardcover. Zustand: Brand New. 288 pages. 10.00x7.00x10.00 inches. In Stock.

Hardcover. Zustand: Brand New. 280 pages. 9.18x6.12x10.00 inches. In Stock.

Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - This book covers various aspects of heavy metal contamination in wastewater and its removal by microbial-based approaches. The heavy metal contamination in water is generally caused due to natural and anthropogenic activities. There are many industrial processes responsible for such a contamination, for example, leather tanning, coal washeries, agriculture activities, chrome plating and paint industries. The industrial effluent directly or indirectly discharges into water sources, and heavy metal containing wastewater decreases the quality of surface water and groundwater. The heavy metal contamination causes various types of health issues in human and other living organisms, including kidney and liver damage, heart failure, mental retardation, cancers, and skin and gastric problems. The high level of heavy metal concentration in the cell generates reactive oxygen species (ROS) which may cause damage to cell organelles.Due to their high toxicity, there is an urgent need to develop effective heavy metal removal method for wastewater treatment. There are several conventional methods available for the removal of heavy metal ions from contaminated sites. These methods have some disadvantages such as the generation of secondary toxic sludge and high operation cost. Hence, it is required to develop cost-effective and eco-friendly methods for decontamination. Microorganisms have tendency to accumulate heavy metal ions into their intracellular space and can grow in various high-stress environments, and microbial-based methods are considered as eco-friendly and cost-effective. Moreover, the integrated approach of wastewater treatment and utilization of microbial biomass for bioenergy production can be beneficial in terms of heavy metal bioremediation and zero waste generation. This book focuses on the heavy metal contamination, their toxicity and microbial methods for the removal of heavy metal ions from contaminated sites.

Hardcover. Zustand: Brand New. 1st edition. 236 pages. 10.00x7.25x0.75 inches. In Stock.

Buch. Zustand: Neu. Neuware - This book provides an in-depth exploration of microbiota profiling and precision medicine, including the underlying mechanisms, delivery methods, treatment strategies, and the impact of biomarker-targeted drug delivery. It incorporates the latest research findings, such as biomarker-targeted drug delivery, clinical assessment and diagnosis, and therapeutic approaches. The book offers a comprehensive overview of the latest developments in biomarker-targeted drug delivery strategies. It addresses the challenges faced by healthcare professionals, offering actionable strategies for effective multidisciplinary care, along with patient and family perspectives, coping mechanisms, and ways to improve quality of life. By combining scientific knowledge, clinical expertise, and patient insights, the book enhances understanding, diagnosis, and treatment options for these complex conditions. These qualities distinguish it from existing publications and make it a valuable resource for readers seeking a thorough and engaging overview of this subject.The chapters cover a broad range of topics, including recent advances in microbiota profiling techniques, microbiota's role in drug metabolism and toxicity, and its immunomodulatory effects. Special focus is given to the involvement of microbiota in neurodegenerative diseases such as Alzheimer's and Parkinson's, emphasizing the therapeutic potential of microbiome-targeted strategies. The authors provide expert analysis on integrating microbiota-derived data with innovative tools like nanotechnology and machine learning to improve drug delivery systems. Readers will also gain practical insights from case studies on microbiota-informed therapies for cancer, autoimmune conditions, and gastrointestinal disorders. This book is essential for researchers, clinicians, academicians, and students working in microbiome science, pharmacology, biotechnology, and precision medicine. It addresses key questions such as biomarker validation, data integration, and the ethical considerations necessary for the clinical use of microbiome-based therapies.

Taschenbuch. Zustand: Neu. Neuware -Il y a environ 200 ans, James Parkinson a décrit les principaux symptômes d'une maladie qui a fini par porter son nom, à savoir la maladie de Parkinson (MP). Progressivement mais sûrement, notre compréhension de la maladie s'est améliorée, mais le traitement efficace de la maladie n'a pas encore été mis au point. La maladie de Parkinson représente un énorme défi pour ceux qui en souffrent et pour ceux qui s'occupent de son suivi. Outre les problèmes communs à d'autres affections neurologiques invalidantes, la prise en charge de la MP doit tenir compte du fait que le fondement du traitement pharmacologique, la lévodopa, peut finalement produire une dyskinésie, également appelée dyskinésie médicamenteuse et fluctuation motrice. En outre, il existe un certain nombre d'agents autres que la lévodopa qui peuvent contribuer à la prise en charge de la MP, et il existe une perspective tentante mais non vérifiée selon laquelle d'autres traitements pourraient protéger contre l'aggravation du handicap neurologique. De plus, dans les pays en développement, les personnes souffrant de la MP n'ont pas accès à la préparation de lévodopa commercialisée. Il est donc nécessaire de faire preuve de beaucoup de discernement pour adapter le traitement individuel et le moment où il est instauré.Books on Demand GmbH, Überseering 33, 22297 Hamburg 76 pp. Französisch.

Taschenbuch. Zustand: Neu. La maladie de Parkinson et Mucuna Magic | Sachchida Nand Rai (u. a.) | Taschenbuch | Französisch | 2022 | Editions Notre Savoir | EAN 9786205289549 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu.

Zustand: New.

Zustand: New.

Taschenbuch. Zustand: Neu. Neuware -Vor etwa 200 Jahren beschrieb James Parkinson die Hauptsymptome einer Krankheit, die schließlich nach ihm benannt wurde: die Parkinson-Krankheit (PD). Allmählich aber sicher hat sich unser Wissen über die Krankheit erweitert, doch eine wirksame Behandlung für die Krankheit wurde noch nicht entwickelt. Die Parkinson-Krankheit stellt eine enorme Herausforderung für die Betroffenen und für diejenigen dar, die sich mit ihrer Überwachung befassen. Zusätzlich zu den Problemen, die auch bei anderen behinderten neurologischen Erkrankungen auftreten, muss bei der Behandlung von Morbus Parkinson die Tatsache berücksichtigt werden, dass die Grundlage der pharmakologischen Behandlung, Levodopa, letztlich Dyskinesien, auch medikamenteninduzierte Dyskinesien und motorische Fluktuationen genannt, hervorrufen kann. Darüber hinaus gibt es neben Levodopa eine Reihe von Wirkstoffen, die bei der Behandlung von Morbus Parkinson hilfreich sein können, und es besteht die verlockende, aber nicht belegte Aussicht, dass andere Behandlungen vor einer Verschlechterung der neurologischen Behinderung schützen könnten. Darüber hinaus haben in den Entwicklungsländern Menschen, die an Morbus Parkinson leiden, keinen Zugang zu dem vermarkteten Levodopa-Präparat. Daher ist bei der Anpassung der individuellen Therapie und dem Zeitpunkt des Behandlungsbeginns ein hohes Maß an Urteilsvermögen erforderlich.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 76 pp. Deutsch.

Taschenbuch. Zustand: Neu. Neuware -Circa 200 anni fa, James Parkinson descrisse i principali sintomi di una malattia che alla fine portò il suo nome, ovvero la malattia di Parkinson (PD). Gradualmente, ma in modo definitivo, le nostre conoscenze sulla malattia sono migliorate, ma non è ancora stato sviluppato un trattamento efficace per la malattia. La malattia di Parkinson rappresenta un'enorme sfida per coloro che ne sono affetti e per coloro che si occupano del suo controllo. Oltre ai problemi comuni ad altre condizioni neurologiche invalidanti, la gestione della PD deve tenere conto del fatto che la base del trattamento farmacologico, la levodopa, può produrre discinesia, detta anche discinesia indotta da farmaci e fluttuazione motoria. Inoltre, oltre alla levodopa, esistono diversi agenti che possono contribuire alla gestione della PD e c'è la prospettiva, allettante ma non verificata, che altri trattamenti possano proteggere dal peggioramento della disabilità neurologica. Inoltre, nei Paesi in via di sviluppo i preparati a base di levodopa commercializzati non sono accessibili ai soggetti affetti da PD. Pertanto, è necessaria una notevole dose di giudizio nel personalizzare la terapia individuale e nel programmare l'inizio del trattamento.Books on Demand GmbH, Überseering 33, 22297 Hamburg 72 pp. Italienisch.

Taschenbuch. Zustand: Neu. Neuware -Há cerca de 200 anos, James Parkinson tinha descrito os principais sintomas de uma doença que acabou por se manter, ou seja, a doença de Parkinson (DP). Gradual mas definitivamente, a nossa compreensão sobre a doença foi reforçada, ainda não foi desenvolvido o tratamento eficaz para a doença. As sobras de DP representam um enorme desafio para aqueles que sofrem da doença e para aqueles que se preocupam com a sua supervisão. Para além dos problemas comuns a outras condições neurológicas incapacitantes, a gestão da DP deve ter em conta o facto de que a base do tratamento farmacológico, a levodopa, pode acabar por produzir discinesia, também chamada discinesia induzida por medicamentos e flutuação motora. Além disso, há uma série de agentes para além da levodopa que podem ajudar na gestão da DP, e há uma perspectiva tentadora mas não verificada de que outros tratamentos possam proteger contra o agravamento da incapacidade neurológica. Além disso, nos países em desenvolvimento, a preparação de levodopa comercializada não é acedida por indivíduos que sofrem de DP. Assim, é necessária uma quantidade substancial de julgamento na personalização da terapia individual e na calendarização do início do tratamento.Books on Demand GmbH, Überseering 33, 22297 Hamburg 76 pp. Portugiesisch.